For example, Nowak et al demonstrated that 6 months treatment with the centrally acting sympatholytic agent, rilmenidine, in patients with essential hypertension was associated with increased adiponectin levels without changes in total body fat content (Nowak et al., 2005). This evidence concerns the gene ADIPOQ and essential hypertension.